This would help explain why the combination therapy with FGFR3 and AKT inhibitors was so effective against PI3K–AKT-activated cervical cancer cells that harbored FGFR3-TACC3 fusion (Fig. 4e). Here, TACC3 is linked to cervical carcinoma.